Methods
Autoimmune and Autoinflammatory Disorders, Sarah Alice, T1D
AUTOIMMUNE DISORDERS, TYPE 1 DIABETES
Edited by: Sarah Alice Long, Benaroya Research Institute, United StatesReviewed by: Howard Davidson, University of Colorado, United States; Helena Reijonen, City of Hope National Medical Center, United StatesThis article was submitted to Autoimmune and Autoinflammatory Disorders: Autoimmune Disorders, a section of the journal Frontiers in ImmunologyGAD-alum given into lymph nodes to Type 1 diabetes (T1D) patients participating in a multicenter, randomized, placebo-controlled double-blind study seemed to have a positive effect for patients with DR3DQ2 haplotype, who showed better preservation of C-peptide than the placebo group. Here we compared the immunomodulatory effect of GAD-alum administered into lymph nodes of patients with T1D versus placebo with focus on patients with DR3DQ2 haplotype.GAD autoantibodies, GADA subclasses, GAD